Oncolytic Virus Immunotherapy Market Growth, Size, Trends Analysis - By Virus Type, By Application, By Route of Administration, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Oncolytic Virus Immunotherapy Market Introduction and Overview

According to SPER market research, 'Global Oncolytic Virus Immunotherapy Market Size- By Virus Type, By Application, By Route of Administration, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Oncolytic Virus Immunotherapy Market is predicted to reach 2945.34 million by 2034 with a CAGR of 22.85%.

Oncolytic virus immunotherapy refers to the use of viruses in the treatment of cancer, aiming to infect and destroy cells that are affected by the disease. Consequently, the naturally occurring virus is engineered to deliver therapeutic payloads to tumors and provide immune-boosting molecules once tumor cells have been infected. The benefits of oncolytic virus immunotherapy include a reduction in tumor burden through virus replication within tumorous cells.

Restraints: The substantial expenses associated with oncolytic virus therapy are a critical obstacle impeding the expansion of the global oncolytic virus therapy market. The creation of such therapies necessitates extensive research and prolonged clinical trials, rendering the process exceedingly costly. A significant portion of these expenses arises from the various phases of clinical trials aimed at assessing the efficacy and safety of these therapies in human participants.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Virus Type, By Application, By Route of Administration, By End-User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Amgen Inc, Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc, Replimune Inc, Siga Technologies, Sorrento Therapeutics Inc, TILT Biotherapeutics, Viralytics Ltd.

Global Oncolytic Virus Immunotherapy Market Segmentation:

By Virus Type: Based on the Virus Type, Global Oncolytic Virus Immunotherapy Market is segmented as; Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Newcastle Disease Virus, Reovirus, Other Virus Type.

By Route of Administration: Based on the Route of Administration, Global Oncolytic Virus Immunotherapy Market is segmented as; Intratumoral, Intravenous, Other Routes of Administration.

By Application: Based on the Application, Global Oncolytic Virus Immunotherapy Market is segmented as; Melanoma, Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Other Application.

By End-User: Based on the End-User, Global Oncolytic Virus Immunotherapy Market is segmented as; Hospitals & Clinics, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-User.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25240

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Oncolytic Virus Immunotherapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oncolytic Virus Immunotherapy Market

7. Global Oncolytic Virus Immunotherapy Market, By Virus Type (USD Million) 2021-2034

7.1. Herpes Simplex Virus (HSV)
7.2. Adenovirus
7.3. Vaccinia Virus
7.4. Newcastle Disease Virus
7.5. Reovirus
7.6. Other Virus Type

8. Global Oncolytic Virus Immunotherapy Market, By Route of Administration (USD Million) 2021-2034

8.1. Intratumoral
8.2. Intravenous
8.3. Other Routes of Administration

9. Global Oncolytic Virus Immunotherapy Market, By Application (USD Million) 2021-2034

9.1. Melanoma
9.2. Breast Cancer
9.3. Lung Cancer
9.4. Ovarian Cancer
9.5. Prostate Cancer
9.6. Other Application

10. Global Oncolytic Virus Immunotherapy Market, By End-User (USD Million) 2021-2034

10.1. Hospitals & Clinics
10.2. Cancer Research Institutes
10.3. Ambulatory Surgical Centers
10.4. Other End-User

11. Global Oncolytic Virus Immunotherapy Market, (USD Million) 2021-2034

11.1. Global Oncolytic Virus Immunotherapy Market Size and Market Share

12. Global Oncolytic Virus Immunotherapy Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Amgen Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Creative Biolabs
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Daiichi Sankyo Company Limited
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Genelux Corporation
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5.Oncorus Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Replimune Inc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Siga Technologies
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Sorrento Therapeutics Inc
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. TILT Biotherapeutics
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Viralytics Ltd
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others